Dupilumab for esophagus muscle function in EoE
Treatments studied
Part of Blood & lymphatic, Digestive system, Ear, nose & throat, Immune system & allergy clinical trials.
This trial tests if dupilumab, a weekly injection, can improve the muscle function of the esophagus in people with eosinophilic esophagitis (EoE) who haven't gotten better with acid-reducing medications. Researchers want to see if it helps with swallowing and reduces inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 22 and 75 years old.
- You have been diagnosed with EoE that did not improve with a type of stomach acid medication called a PPI.
- You are willing to receive a weekly injection (shot) of dupilumab for 12 weeks and follow the study schedule.
- You have not taken steroid medications (by mouth, inhaler, or IV) in the 8 weeks before starting the trial.
- You have not used dupilumab before or taken part in another dupilumab study.
- You do not have certain serious medical conditions like active infections or recent cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two medicines—Eohilia (an oral steroid) and Dupixent (an injectable biologic)—to see which one better helps widen the esophagus in people with eosinophilic esophagitis (EoE). It may help you if you have active EoE and are looking for a new treatment option.
This trial tests if dupilumab can help young children with eosinophilic esophagitis (EoE), a condition that causes swelling in the esophagus. It may reduce symptoms and improve how the esophagus heals.
This study looks at how the immune system and the esophageal barrier function in people with eosinophilic esophagitis (EoE) compared to those without. It involves taking biopsies during an upper endoscopy to understand the disease better. The results may help improve treatments for EoE.
This study looks at how well Dupilumab works over time in people aged 12 and older with eosinophilic esophagitis (EoE) whose symptoms are not well controlled by standard treatments. It aims to understand the medicine's effects in everyday medical practice.
This trial tests if dupilumab can help people with hard-to-treat stomach ulcers linked to eosinophilic gastrointestinal disorders (EGIDs), where a type of white blood cell builds up in the gut. It may offer a new option for those who haven't gotten better with other treatments.
This study compares two treatments for EoE that has caused narrowing in the esophagus: dupilumab (a biologic injection) versus a topical corticosteroid (a swallowed steroid). It aims to see which works better for teens and young adults to improve swallowing and reduce inflammation.
Hear when a new Eosinophilic Esophagitis (EoE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.